NPS delays US submission for biologic-device combo Natpara
This article was originally published in Clinica
Executive Summary
NPS Pharmaceuticals plans to submit a marketing application for its hypoparathyroidism biologic-device combination therapy Natpara (recombinant human parathyroid hormone) to the US FDA have been delayed until mid-2013 after the agency's medical device division called for a modification in the firm's instructions for using the medicine's injection pen device.